Dr. Rose examines why PSA screening alone is insufficient and how risk-adapted strategies can improve detection of aggressive prostate cancer while reducing harm.
Read More
Dr. Bagrodia explains why abandoning PSA screening was the wrong solution and how smarter, risk-based strategies can improve prostate cancer outcomes.
Read More
Dr. Peter Carroll reviews PSA screening, MRI integration, and shared decision-making for early prostate cancer detection.
Read More
Brian T. Helfand, MD, PhD, addresses genetic and polygenic risk scoring in identifying men at higher risk of developing prostate cancer.
Read More
Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert, reflects on the significant advancements in prostate imaging over the last decade, emphasizing the transformative role of MRI. A central question in this 15-minute presentation is whether prostate cancer can be diagnosed and managed without a biopsy. While biopsies are the current standard, they carry risks such as sepsis, patient discomfort, and financial burden.
The PROMIS study demonstrated MRI’s ability to detect all Gleason 4+3 cancers, though it also revealed MRI’s high number of false positives. Combining PSMA PET with MRI improves sensitivity to 97%, particularly for detecting clinically significant cancers, but specificity remains a challenge, raising concerns about unnecessary treatment. New scoring systems, like the P score, integrate PET avidity and PI-RADS scores to refine risk assessment and treatment decisions.
Kasivisvanathan discusses the concept of “biopsy-light” pathways, citing cohorts where patients undergo fewer biopsies, with monitoring driven by MRI and PSA changes. This approach shows promising compliance and oncological outcomes comparable to standard active surveillance but with less patient burden. Despite advancements, a fully biopsy-free pathway remains unfeasible due to limitations in MRI standardization, interpretation variability, and a lack of high-volume data.
Read More
R. Jonathan Henderson, MD, examines prostate cancer screening, emphasizing key trials and ongoing global efforts to improve detection.
Read More
Sigrid V. Carlsson, MD, PhD, MPH, explores the role of genetics in risk-stratified prostate cancer screening.
Read More
Juan Javier-DesLoges, MD, MS, focuses on contemporary advancements in prostate cancer detection, emphasizing the integration of biomarkers and MRI for biopsy decision-making. In this 5-minute presentation, he references recent guidelines, which advocate biomarkers and MRI as tools for determining the necessity of biopsies. Studies comparing biomarkers such as 4K, PHI, SelectMDx, and XODX illustrate their ability to enhance the specificity and accuracy of cancer detection compared to PSA alone.
Dr. Javier-DesLoges stresses that MRI further refines risk stratification when combined with biomarkers. He underscores the complementary role of these tools, advocating their combined use to optimize diagnostic outcomes for patients with intermediate PSA levels.
Read More
Peter A. Pinto, MD, underscores the evolving role of MRI as a critical biomarker in urologic oncology, particularly for prostate cancer detection, staging, and treatment planning.
In this 12-minute conversation, Dr. Pinto highlights MRI’s unique position as a diagnostic and procedural adjunct, emphasizing its ability to improve biopsy accuracy, reduce over-diagnosis of low-grade cancers, and enhance focal therapy targeting. He shares that MRI provides actionable insights that enhance clinical decision-making by correlating radiologic findings with pathological outcomes. Further, the potential of MRI as a screening tool is explored, with promising advancements in shorter, contrast-free scans. Dr. Pinto also addresses the integration of AI for tumor identification, segmentation, and quality control, presented as a pathway to overcoming these limitations.
Read More
Sadhna Verma, MD, MBA, FSAR, begins this 20-minute presentation by emphasizing the exponential growth of prostate MRI usage and its critical role in prostate cancer detection. Before diving into PI-RADS, the multiparametric MRI approach is explained. T2-weighted sequences are highlighted as the best for anatomical visualization.
PI-RADS scoring, a standardized Likert-like system ranging from 1 to 5, assesses the likelihood of malignancy of a lesion based on size, location, and imaging characteristics. PI-RADS version 2.1 introduces refinements, particularly for transition zone lesions. The updated guidelines also incorporate templates to standardize reporting and emphasize quality assurance. Central zone tumors are recognized for their aggressive nature and specific imaging features.
Dr.Verma shares images to illustrate the scoring refinements of PI-RADS version 2.1. Despite advancements, quality variability in imaging and interpretation remains a concern. Collaborative initiatives led by the American College of Radiology aim to enhance diagnostic accuracy. Dr. Verma emphasizes the need for ongoing quality assurance and training to address current limitations and improve clinical outcomes.
Read More
Mukesh Harisinghani, MD, Harvard University Medical School, presents a compelling talk on achieving an under-15-minute bi-parametric MRI protocol for prostate cancer imaging.
In this 11-minute presentation, Dr. Harisinghani highlights that multiparametric MRI, the standard for detecting clinically significant cancer, requires lengthy protocols. Transitioning to bi-parametric MRI eliminates the need for contrast enhancement, maintaining diagnostic accuracy while significantly reducing scan time.
Harisinghani emphasizes the role of deep learning algorithms in optimizing image quality without compromising timing. He cites studies, including the PRIME study, demonstrating that bi-parametric MRI detects clinically significant cancers.
Read More
Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, discusses the IMPACT and PROFILE studies, which focus on prostate cancer risk and detection in genetically predisposed populations.
In this 11-minute presentation, McHugh shows that both studies emphasize early detection in genetically high-risk men, particularly BRCA mutation and Lynch syndrome carriers. Updated methodologies incorporate multi-ancestry PRS and expanded genetic sequencing to refine risk assessment and address disparities. These findings highlight the importance of precision screening in managing prostate cancer in diverse, high-risk populations.
Read More